# Table of Contents

1. Pre-processing  
   1.1. PDX pre-processing  
2. Quality control  
3. Somatic variant calling pipeline  
   3.1. Variant calling  
   3.2. Variant merging  
   3.3. Tumor-only analysis  
4. Somatic variant annotation  
   4.1. SNVs and Indels  
   4.2. CNVs  
5. Somatic variant filtering  
   5.1. Panel of Normals  
   5.2. Common germline variants  
   5.3. Allele counts  
   5.4. All Somatic and High-confidence variants  
6. Germline variant analysis  
7. MSI detection  
8. HLA-typing  
9. Mutational signature analysis  
10. References
1. Pre-processing

Sequencing reads for the tumor and normal samples are first quality and adapter trimmed using TrimGalore (v0.4.0)\(^1\). The trimmed reads are then aligned to the reference genome using BWA-MEM (v0.7.15) \((1)\). NYGC’s ShortAlignmentMarking\(^2\) (v2.1) is used to mark short reads as unaligned. This tool is intended to remove spurious alignments resulting from contamination (e.g. saliva sample bacterial content) or from too aggressive alignments of short reads the size of BWA-MEM’s 19bp minimum seed length. These spurious alignments result in pileups in certain locations of the genome and can lead to erroneous variant calling.

GATK (v4.1.0) \((2)\) FixMateInformation is run to verify and fix mate-pair information, followed by Novosort (v1.03.01) markDuplicates to merge individual lane BAM files into a single BAM file.

---

\(^1\) https://github.com/FelixKrueger/TrimGalore

\(^2\) https://github.com/nygenome/nygc-short-alignment-marking
per sample. Duplicates are then sorted and marked, and GATK’s base quality score recalibration (BQSR) is performed. The final result of the pre-processing pipeline is a coordinate sorted BAM file for each sample.

1.1. PDX pre-processing

Patient-derived xenograft (PDX) samples undergo an additional pre-processing step. After the adapter and quality trimming step, mouse reads are detected and removed from the FASTQ files by aligning the data to a combined reference of mouse (GRCm38) and human (GRCh37). All read pairs with both reads mapping to mouse or one read mapping to mouse and the other unmapped are excluded from subsequent processing and analyses steps.

2. Quality control

Once preprocessing is complete, we compute a number of alignment quality metrics such as average coverage, %mapped reads and %duplicate reads using GATK (v4.1.0) and an autocorrelation metric (adapted for WGS from(3)) to check for unevenness of coverage. We also run Conpair (4), a tool developed at NYGC to check the genetic concordance between the normal and the tumor sample and to estimate any inter-individual contamination in the samples.

3. Somatic variant calling pipeline

3.1. Variant calling

The tumor and normal bam files are processed through NYGC’s variant calling pipeline which consists of MuTect2 (GATK v4.0.5.1) (5), Strelka2 (v2.9.3) (6) and Lancet (v1.0.7) (7) for calling Single Nucleotide Variants (SNVs) and short Insertion-or-Deletion (Indels), SvABA (v0.2.1) (8) for calling Indels, FACETS (v0.5.5) (9) and EXCAVATOR2 (v1.1.2) (10) for calling Copy-number variants (CNVs). For CNVs, only FACETS results are used for all subsequent analyses.

3.2. Variant merging

Next, the calls are merged by variant type (SNVs, Multi Nucleotide Variants (MNVs) and Indels). MuTect2 and Lancet call MNVs, however Strelka2 does not and it also does not provide any phasing information. So to merge such variants across callers, we first split the MNVs called by MuTect2 and Lancet to SNVs, and then merge the SNV callsets across the different callers. If the caller support for each SNV in an MNV is the same, we merge them back to MNVs. Otherwise those are represented as individual SNVs in the final callset. Lancet is the only tool that calls deletion-insertion (delins or COMPLEX) events. Other tools may represent the same event as separate indel and/or SNV variants. Such events are rare, especially in the exonic regions and difficult to merge. We therefore do not merge COMPLEX calls with SNVs and Indels calls from other callers.
3.3. Tumor-only analysis

When a matched normal sample is not available, in its place we use a "contemporary normal", that is, DNA from the HapMap sample NA12878 that was prepped and sequenced using the same protocol as the tumor sample. Using a contemporary normal removes some of the false positives that are due to library preparation and sequencing (that would manifest in the same way in the tumor and NA12878), as well as some germline variants that are common to the tumor sample and NA12878.

4. Somatic variant annotation

4.1. SNVs and Indels

SNVs and Indels are annotated with Ensembl as well as databases such as COSMIC (v86) (11), 1000Genomes (Phase3) (12), ClinVar (201706) (13), PolyPhen (v2.2.2) (14), SIFT (v5.2.2) (15), FATHMM (v2.1) (16), gnomAD (r2.0.1) (17) and dbSNP (v150) (18) using Variant Effect Predictor (v93.2) (19).

4.2. CNVs

Segments with log2 > 0.2 are categorized as amplifications, and segments with log2 < -0.235 are categorized as deletions (corresponding to a single copy change at 30% purity in a diploid genome, or a 15% Variant Allele Fraction). CNVs of size less than 20Mb are denoted as focal and the rest are considered large-scale.

We use bedtools (20) for annotating CNVs. All predicted CNVs are annotated with germline variants by overlapping with known variants in 1000 Genomes and Database of Genomic Variants (DGV) (21). Cancer-specific annotation includes overlap with genes from Ensembl (22) and Cancer Gene Census in COSMIC, and potential effect on gene structure (e.g. disruptive, intronic, intergenic). Further annotations include sequence features within breakpoint flanking regions, e.g. mappability, simple repeat content and segmental duplications.

5. Somatic variant filtering

5.1. Panel of Normals

The Panel of Normals (PON) filtering removes recurrent technical artifacts from the somatic variant callset (5). The Panel of Normals for SNVs and indels was created with whole-exome sequencing data from normal samples from 45 unrelated individuals sequenced in-house. We ran MuTect2 in artifact detection mode on these samples and created a PON list file with sites that were seen in two or more individuals. We use this list to filter the somatic variants in the merged SNV and indel files.
5.2. Common germline variants

In addition to the PON filtering, we remove SNVs and Indels that have minor allele frequency (MAF) of 1% or higher in either 1000Genomes (phase 3) or gnomAD (r2.0.1) (23). CNVs are annotated with DGV and 1000 Genomes but not filtered.

5.3. Allele counts

Since our variant callsets are generated by merging calls across callers, and each of them reported different allele counts, we report final chosen allele counts for SNVs and indels. For SNVs, and for indels less than 10nt in length, these are computed as the number of unique read-pairs supporting each allele using the pileup method, with minimum mapping quality and base quality thresholds of 10 each.

For larger indels and complex (deletion-insertion) events, we choose the final allele counts reported by the individual callers Strelka2, MuTect2, Lancet, in that order. For indels larger than 10nt that are only called by SvABA, we do not report final allele counts and allele frequencies because SvABA does not report the reference allele count, making it difficult to estimate the variant allele frequency.

We then use these final chosen allele counts and frequencies to filter the somatic callset. Specifically, we filter any variant for which the variant allele frequency (VAF) in the tumor sample is less than 0.0001, or if the VAF in the normal sample is greater than 0.2, or if the depth at the position is less than 2 in either the tumor sample or the normal sample. We also filter variants for which the VAF in normal sample is greater than the VAF in tumor sample.

5.4. All Somatic and High-confidence variants

SNVs and Indels that pass all of the above-mentioned filters are included in our final somatic callset (All Somatic). Subset of All Somatic variants that are called by 2 or more variant callers are considered to be high confidence (HighConf).

6. Germline variant analysis

We call germline SNPs and indels on the matched normal sample using GATK HaplotypeCaller (v3.5), which generates a single-sample GVCF. We then run GATK’s GenotypeGVCF to perform single sample genotype refinement and output a VCF, followed by variant quality score recalibration (VQSR) for variant filtering (at tranche 99.6%). Next, we run Variant Effect Predictor (v93.2) to annotate the variants with Ensembl as well as databases such as COSMIC (v86), 1000Genomes (Phase3), gnomAD (r2.0.1), dbSNP (v150), ClinVar (201805), Polyphen2 (v2.2.2) and SIFT (v5.2.2).

7. MSI detection

We run MANTIS (v1.0.4) (24) for Microsatellite Instability (MSI) detection in microsatellite loci (found using RepeatFinder, a tool included with MANTIS) within the target intervals. A sample is
considered to be microsatellite unstable if its Step-Wise Difference score reported by MANTIS is greater than 0.4 (or 0.62\textsuperscript{3} in absence of a matched-normal). Otherwise it is considered to be microsatellite stable (MSS).

8. HLA-typing

We run OptiType (v1.3.2) (25) and Kourami\textsuperscript{4} (v0.9.6) (26) on the matched normal sample for Human Leukocyte Antigen (HLA)-typing. OptiType predicts major histocompatibility complex (MHC) Class I alleles (HLA-A, HLA-B, HLA-C), whereas Kourami predicts both MHC Class I and Class II alleles (HLA-DR, HLA-DQ, HLA-DR).

9. Mutational signature analysis

We run deconstructSigs (v1.8.0) (27) on the High Confidence somatic SNV callset within autosomes to estimate contribution of known COSMIC mutational signatures (v2 - March 2015)\textsuperscript{5} in the tumor sample. The SNV mutation count data is normalized to reflect the absolute frequency of each trinucleotide context as it would occur across the whole genome. For this tri.counts.method parameter in deconstructSigs is set to 'exome2genome', and a custom exome trinucleotide counts file based on the target interval is provided.

\textsuperscript{3} Threshold chosen based on internal benchmarking

\textsuperscript{4} Note: Kourami only supports build 38 of the human genome and therefore is not run if data is aligned to GRCh37

\textsuperscript{5} https://cancer.sanger.ac.uk/cosmic/signatures_v2
10. References


